Skip to main content

Generalized Lipodystrophy

1
Pipeline Programs
2
Companies
6
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Amryt Pharma
Amryt PharmaUK - London
1 program
1
metreleptinPhase 45 trials
Active Trials
NCT06502990Recruiting15Est. Sep 2026
NCT06679270Recruiting24Est. Dec 2028
NCT06484868Recruiting12Est. Feb 2028
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Amryt Pharmametreleptin
Amryt Pharmametreleptin
Amryt Pharmametreleptin
Amryt Pharmametreleptin
Amryt Pharmametreleptin
Amryt Pharmametreleptin

Clinical Trials (6)

Total enrollment: 224 patients across 6 trials

NCT06484868Amryt Pharmametreleptin

Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Start: Feb 2024Est. completion: Feb 202812 patients
Phase 4Recruiting
NCT06502990Amryt Pharmametreleptin

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Start: May 2025Est. completion: Sep 202615 patients
Phase 3Recruiting
NCT06679270Amryt Pharmametreleptin

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Start: Oct 2024Est. completion: Dec 202824 patients
Phase 3Recruiting
NCT05164341Amryt Pharmametreleptin

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

Start: Dec 2021Est. completion: Oct 202669 patients
Phase 3Active Not Recruiting
NCT05351164Amryt Pharmametreleptin

Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

Start: Aug 2023Est. completion: Oct 20284 patients
Phase 2Active Not Recruiting
NCT02325674Amryt Pharmametreleptin

MEASuRE: Metreleptin Effectiveness And Safety Registry

Start: Oct 2016Est. completion: Oct 2031100 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 224 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.